HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd
Christian F. Singer(Comprehensive Cancer Center Vienna), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Stephanie Strobl, Florian Fitzal, Angelika Pichler, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Martin Filipits(University of Vienna), Lidija Sölkner(Austrian Breast & Colorectal Cancer Study Group), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Christine Deutschmann(Universitätsklinik für Frauenheilkunde und Geburtshilfe), Richard Greil(Paracelsus Medical University), Rupert Bartsch(Universitätszahnklinik Wien), Magdalena Schwarz(Austrian Breast & Colorectal Cancer Study Group), Daniel Egle(Innsbruck Medical University), Stephen Esker(Daiichi Sankyo (United States)), Stephan Jahn(Medical University of Graz), Dalila Sellami(Daiichi Sankyo (United States)), Ulrike Heber(Comprehensive Cancer Center Vienna), Jana Machacek‐Link(Austrian Breast & Colorectal Cancer Study Group), Michael Seifert(Zimmer Biomet (Germany)), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), Georg Pfeiler(Comprehensive Cancer Center Vienna), Christoph Suppan(Medical University of Graz), Magdalena Ritter(Innsbruck Medical University), Günther Steger(Barwon Health), Anu Santhanagopal(Daiichi Sankyo (United States)), Charlotte Mang‐Manger(Comprehensive Cancer Center Vienna)
Cited by 3
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k